11th Annual Personalized Medicine Conference Program

November 18-19, 2015
Joseph B. Martin Conference Center at Harvard Medical School, Boston

Join the conversation at #PMConf
Highlights Of Past Conferences
November 18, 2015

Dear Colleague:

Welcome to the 11th Annual Personalized Medicine Conference! We and the other members of the Conference Organizing Committee, whose names you will see on the last page of this program, are pleased to offer this meeting co-hosted by Partners HealthCare, Harvard Medical School and Harvard Business School in association with the American Association for Cancer Research, American Medical Association, American Society for Human Genetics and the Personalized Medicine Coalition. We offer our profound thanks to the speakers, panelists, our generous Supporters and the Conference staff for all that they do to make this meeting meaningful and worthwhile.

The motivation for organizing the first Personalized Medicine Conference in 2005, was the belief that personalized medicine is going to play a very important role in managing health and disease and to promote this notion it is important to bring together the diverse stakeholders and have them engage in lively discussions. The subtitle of our first meeting was “Promises and Prospects.” The sessions at that meeting were focused primarily on instances in which there already was some success and on trying to help shape an awareness of what personalized medicine could mean, particularly in certain focused clinical areas. It is deeply satisfying to see the progress that has been made across a broad clinical spectrum in the decade since that meeting, as well as in the rapid development of ever-improving testing and diagnostic technologies, analytical capabilities and information resources. “Personalized Medicine” is no longer simply a catch-phrase. It is a new paradigm for improving healthcare around the world and this 11th conference year we are “Beginning the Second Decade.”

Many challenges remain in personalized medicine being widely adopted. As we have noted previously, our Personalized Medicine Conference has as its core purpose to provide a forum where diverse stakeholders can engage in vigorous intellectual discussion of issues in implementing personalized medicine. This year’s meeting will celebrate the accomplishments of the past years and will address important issues such as regulation and reimbursement that are critical to the continued development of personalized medicine.

Eleven years ago we started this meeting in association with the Personalized Medicine Coalition which is now moving forward in their eleventh year. Together we have accomplished great strides in personalized medicine and we are proud of our association. We hope you will find this year’s meeting engaging and stimulating and that you will add your own wisdom and perspective to the conversations. It also should be an opportunity for you to renew friendships, expand acquaintances and meet new people whose knowledge will enhance your own understanding of personalized medicine. Welcome, again, to what we trust you will find a productive and enjoyable meeting.

Sincerely,

Scott T. Weiss, M.D., M.S.
Scientific Director
Partners HealthCare Personalized Medicine
Professor of Medicine,
Harvard Medical School
Co-chair, Conference Organizing Committee

Raju Kucherlapati, Ph.D.
Paul C. Cabot Professor of Genetics and
Professor of Medicine, Harvard Medical School;
Co-chair, Conference Organizing Committee
A THANK YOU TO OUR SUPPORTERS

This conference is presented by Partners HealthCare Personalized Medicine, Harvard Medical School and Harvard Business School and in association with the American Association for Cancer Research; American Medical Association; American Society for Human Genetics and the Personalized Medicine Coalition.

**GOLD**

AstraZeneca  
ORACLE  
Lilly  
GE

**SILVER**

Astellas Oncology  
Takeda  
Millennium The Takeda Oncology Company  
PMC Personalized Medicine Coalition  
Pfizer  
Foundation Medicine  
Intermountain Healthcare
Bronze

BioGen Idec

Raindance Technologies

EAC

Metamark

Inova

Molecular Health

PwC

Regeneron

SLONE Partners

Contributing

We want you to know

Aetna

GNS Healthcare

Leerink

Forum Pharmaceuticals

Third Rock Ventures

Agios
8:00 a.m.  Welcome  Raju Kucherlapati, Ph.D.
Paul C. Cabot Professor of Genetics, Professor of Medicine, Harvard Medical School
AND
Scott Weiss, M.D., M.S.
Scientific Director, Partners HealthCare Personalized Medicine; Associate Director, Channing Laboratory; Professor of Medicine, Harvard Medical School
Greeting
Ralph Snyderman, M.D.
Chancellor Emeritus, James B. Duke Professor of Medicine, Duke University
8:30 a.m.  Keynote Speaker  Kathy Hudson, Ph.D.
Deputy Director for Science, Outreach, and Policy, National Institutes of Health (NIH).
9:00 a.m.  Panel: Investments in Personalized Medicine
During the past several years there have been increased levels of financial investments in fields related to Personalized Medicine. The new initiative on Precision Medicine by President Obama is also fueling discussions about new types of investments. This panel will explore the reasons for interest in investing in Personalized Medicine products and how both large and small companies are developing programs to expand their interest in this area.
Opening Speaker and Moderator: Sue Siegel
Chief Executive Officer, GE Ventures & healthymagination, GE
Panelists:
Sean George, Ph.D.
President and COO, Co-Founder, Invitae
Mark Levin
Partner, Third Rock Ventures
Kimberly Popovits
Chairman, Chief Executive Officer and President, Genomic Health
10:00 a.m.  Networking Break
10:30 a.m.  “Precision Trials Challenge”  Richard Hamermesh, DBA
Senior Fellow and Former MBA Class of 1961 Professor of Management Practice, Harvard Business School
with
Robert Kraft
Chairman and Chief Executive Officer, Kraft Group will introduce the Harvard Business School’s “Precision Trials Challenge”
11:00 a.m.  Panel: Precision Medicine Initiative in US and Abroad
President Obama has announced a Precision Medicine Initiative in the US earlier this year. A part of that effort is to collect information from a very large cohort of patients. Such efforts have been initiated at many Institutions in the US and around the world. This panel will discuss the successes of these efforts and the challenges they face.
Opening Speaker and Moderator: Elizabeth Karlson, M.D.
Co-Investigator, Partners Biobank, Partners HealthCare Personalized Medicine; Associate Professor of Medicine, Harvard Medical School
Panelists:
Hadi Abderrahim, M.D., Ph.D., MBA
Managing Director, Qatar Biobank
Taro Inada, Ph.D.
Global Innovation General Manager, Denka Co., Ltd.
Nahid Turan, Ph.D.
Principal Investigator, National Institute of General Medical Sciences Human Genetic Cell Repository, Coriell Institute for Medical Research
12:00 NOON  Luncheon
1:00 p.m.  Keynote  Robert Califf, M.D.
Deputy Commissioner, US FDA Office of Medical Products and Tobacco, Food and Drug Administration
1:30 p.m.  **Panel: Precision Medicine in Community Healthcare Settings**

Much of the U.S. population relies on their local physicians and hospitals for their healthcare needs. Many of these community based physician practices have decided that implementation of the principles of personalized medicine is critical to the well being of the patients they serve. This panel will provide examples of the implementation of personalized medicine in different settings.

**Opening Speaker and Moderator:**
**Barbara McAneny, M.D.**
Chief Executive Officer, New Mexico Oncology Hematology Consultants, Ltd.
Immediate Past Chair, Board of Trustees, American Medical Association

**Panelists:**
**Lynn Dressler, Dr. P.H.**
Director, Personalized Medicine, Mission Health

**David Ledbetter, Ph.D., FACMG**
Executive Vice President and Chief Scientific Officer, Geisinger Health System

**John Niederhuber, M.D.**
Chief Executive Officer, Inova Translational Medical Institute

2:30 p.m.  **Mini Keynote**

**Role of Biomarker Qualification in Personalized Medicine**

**Speaker:**
**Anna Barker, Ph.D.**
Co-Director, Complex Adaptive Systems Initiative
Director, National Biomarker Development Alliance (NBDA); Professor, School of Life Sciences, Arizona State University

2:45 p.m.  **Break**

3:15 p.m.  **Conversation: PM Conference Associations Perspectives From Professional Societies**

Our Conference is organized in association with the Personalized Medicine Coalition, American Association for Cancer Research, American Medical Association and the American Society for Human Genetics. All of these and many other scientific and medical organizations have established programs to educate their membership about the principles of personalized medicine and how it is influencing scientific and medical discovery as well implementation to improve human health. Representatives from these different organizations will discuss ways to improve the literacy on personalized medicine.

**Opening Speaker and Moderator:**
**Cynthia Casson Morton, Ph.D.**
William Lambert Richardson Professor of OB/Gyn and Reproductive Biology and Professor of Pathology, Harvard Medical School; Director of Cytogenetics, Brigham and Women’s Hospital

**Panelists:**
**José Baselga, M.D., Ph.D.**
Physician in Chief and Chief Medical Officer, Memorial Sloan Kettering Cancer Center

**Richard Friedberg, M.D., Ph.D., FCAP**
Chair, Department of Pathology, Diagnostic Medicine Services, Baystate Health

**James Madara, M.D.**
Executive Vice President and Chief Executive Officer, American Medical Association

4:15 p.m.  **Panel: Personalized Medicine Around the World**

Personalized Medicine cuts across all disciplines of biology and medicine and does not have any national boundaries. However the healthcare systems in each country around the world are different and each country is taking its own unique path toward providing personalized medicine to its people. We will hear different examples from the two largest countries, China and India as well as perspectives from international business organizations.

**Opening Speaker and Moderator:**
**Gary Palmer, M.D., J.D., M.B.A., M.P.H.**
Chief Medical Officer, NantHealth

**Panelists:**
**Vijay Chandru, Ph.D.**
Co-Founder and Chairman, Strand Life Sciences

**Xishan Hao, M.D., FACS**
Professor, Academician of Chinese Academy of Engineering; President, Chinese Anti-Cancer Association; Director, Tianjin Cancer Research Institute, Tianjin, China

**Jack Wang**
Founder and Chief Executive Officer, Biomobie

5:15 p.m.  **Reception**

**Elements Café**
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Leader</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m.</td>
<td>Opening</td>
<td>Scott Weiss, M.D., M.S.</td>
</tr>
<tr>
<td></td>
<td>Opening Remarks and Introduction</td>
<td>Scientific Director, Partners HealthCare Personalized Medicine;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Associate Director, Channing Laboratory; Professor of Medicine, Harvard Medical</td>
</tr>
<tr>
<td>8:15 a.m.</td>
<td>HBS Case Presentation:</td>
<td>Robert Higgins</td>
</tr>
<tr>
<td></td>
<td>Building a Personalized Medicine Company: What Does It Take?</td>
<td>Senior Lecturer of Business Administration, Harvard Business School; Co-founder,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Causeway Media Partners and Highland Capital Partners</td>
</tr>
<tr>
<td>8:30 a.m.</td>
<td>Keynote</td>
<td>Mikael Dolsten, M.D., Ph.D.</td>
</tr>
<tr>
<td></td>
<td>Looking at Personalized Medicine from a Pharmaceutical Perspective</td>
<td>President, Worldwide Research and Development, Pfizer Inc</td>
</tr>
<tr>
<td>9:30 a.m.</td>
<td>Networking Break</td>
<td></td>
</tr>
<tr>
<td>10:00 a.m.</td>
<td>Presentation of Personalized Medicine</td>
<td>Francis S. Collins, M.D., Ph.D.</td>
</tr>
<tr>
<td></td>
<td>Coalition’s 11th Annual Award for Leadership in Personalized Medicine</td>
<td>Director, National Institutes of Health (NIH)</td>
</tr>
<tr>
<td>10:30 a.m.</td>
<td>Panel: Novel Efforts in Personalized Medicine</td>
<td>Deborah Dunsire, M.D.</td>
</tr>
<tr>
<td></td>
<td>As the knowledge base of personalized medicine and the development</td>
<td>Opening Speaker and Moderator:</td>
</tr>
<tr>
<td></td>
<td>of new technologies that support it are being developed, it is useful</td>
<td>Deborah Dunsire, M.D.</td>
</tr>
<tr>
<td></td>
<td>to learn about how this field is impacting many diverse fields and</td>
<td>President and Chief Executive Officer, FORUM Pharmaceuticals</td>
</tr>
<tr>
<td></td>
<td>how novel technologies and information systems are influencing it.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>This panel provides a sampling of companies and how they are</td>
<td></td>
</tr>
<tr>
<td></td>
<td>enhancing personalized medicine.</td>
<td></td>
</tr>
<tr>
<td>11:00 a.m.</td>
<td>Keynote</td>
<td>Sir John Chisholm</td>
</tr>
<tr>
<td>12:00 NOON</td>
<td>Genomics England</td>
<td>Executive Chair, Genomics England</td>
</tr>
<tr>
<td>12:30 p.m.</td>
<td>Bag Lunch</td>
<td>Open Seating</td>
</tr>
</tbody>
</table>
1:30 p.m. **Panel: Innovators in Personalized Medicine**

The movement in any field of medicine is dependent upon the organizations and its leaders. There are a large number of innovative ideas that are transforming the way we provide healthcare to patients and in this panel we will hear examples of how successful companies are built and how some large companies are increasing their investments in personalized medicine.

**Opening Speaker and Moderator:**
**Michael Pellini, M.D., M.B.A.**
President and Chief Executive Officer, Foundation Medicine

**Panelists:**
**Christine Cournoyer**
Chief Executive Officer, N-of-One, Inc.

**Michael Reitermann**
Chief Executive Officer, Siemens Healthcare Diagnostics, Member of Executive Management, Siemens

**George D. Yancopoulos, M.D., Ph.D.**
President, Regeneron Laboratories and Chief Scientific Officer, Regeneron Pharmaceuticals, Inc.

---

2:30 p.m. **Keynote**

**Opportunities in Personalized Medicine: Redefining the Value of Care**

**Speaker:**
**Paul Hudson**
President, AstraZeneca US
Executive Vice President, North America

---

3:00 p.m. **Closing Remarks**

**Raju Kucherlapati, Ph.D.**
Paul C. Cabot Professor of Genetics, Professor of Medicine, Harvard Medical School
Hadi Abderrahim, M.D., Ph.D., M.B.A.

Hadi Abderrahim, M.D., Ph.D., M.B.A. has experience in academic settings (CEPH, Cold Spring Harbor, Stanford University) as well as Biotech and Pharma. Dr. Abderrahim is a biotechnology and pharmaceutical executive with more than 20 years experience in human genetics and biomarker development and studying the effect of genetic factors on reactions to drugs and personalised medicine.

As Head of Genetics and Biomarkers at Merck Serono, a pharmaceutical company based in Geneva, Dr. Abderrahim oversaw the strategies for patient stratification in personalized medicine and established a central Biobank based in Italy.

Prior to that, as Head of Genetics and Genomics Platforms at Genset in Paris, Dr. Abderrahim set up a genetic and genomic platform with application to studying complex traits and diseases and a Pharmacogenetics team devoted to identify responders to drug treatments. He obtained his M.D. specialty in Genetic counseling from Hopital Necker, Paris, and he has a Ph.D. in Human Genetics and an executive MBA from HEC Paris.

S. Roopom Banerjee

S. Roopom Banerjee, President and Chief Executive Officer, joined RainDance in 2010 from Leerink Swann where he was a Director of Healthcare Investment Banking and led the Life Science Tools and Diagnostics sector. Previously, Mr. Banerjee held positions at McKinsey & Company and Goldman Sachs advising Fortune 500 healthcare companies globally on corporate and growth strategy, product development and launch strategy, international expansion, and mergers and acquisitions. He has successfully completed over 50 transactions, including IPOs, Follow-on, PIPE/RODs, private placements and fixed income financings as well as mergers and acquisitions.

Prior to Wall Street, Mr. Banerjee was a cancer and genomics research scientist at the Dana Farber Cancer Institute, the Whitehead Institute/MIT Human Genome Project, and at the Massachusetts General Hospital Cancer Center. He holds an M.P.P. from the Kennedy School of Government at Harvard University and dual B.S. degrees in Biology and Economics from M.I.T.

Anna D. Barker, Ph.D.

Anna Parker, Ph.D., Co-Director of Complex Adaptive Systems (CAS) at Arizona State University (ASU), designs and implements transformative knowledge networks specifically directed toward addressing major problems in healthcare. These multi-sector networks serve as a foundation for the development of new research models that leverage convergent knowledge, innovative teams and novel funding approaches to better prevent and treat acute and chronic disease and address major healthcare problems. CAS at ASU serves as an organizing construct to approach understanding and solving multi-dimensional problems in the biomedical and health sciences. Several initiatives are underway including a newly launched national non-profit trans-sector effort in biomarker discovery and development (The National Biomarker Development Alliance); an international multidisciplinary alliance that is re-thinking glioblastoma multiforme” (GBM) and creating new research opportunities; and a U.S.-Chinese Alliance that will pursue collaborative research in evolutionary medicine and cancer (based on the Physical Sciences-Oncology Centers model she developed at the National Cancer Institute).

Prior to joining ASU, Dr. Barker served several years as the Deputy Director and Deputy Director for Strategic Scientific Initiatives for the National Cancer Institute (NCI), National Institutes of Health (NIH). At the NCI, she developed and led or co-led a number of trans-disciplinary programs including the Nanotechnology Alliance for Cancer; The Cancer Genome Atlas (TCGA); Clinical Proteomics Technologies Initiative for Cancer; and the Physical Sciences—Oncology Centers—PS-OCs. Under her leadership, the NCI also developed major initiatives in bio specimen science and bioinformatics. Dr. Barker was founding co-chair of the NCI-FDA Interagency Task Force (IOTF) and was founding co-chair of the Cancer Steering Committee of the FNIH Biomarkers Consortium (FNIH-BC). Among achievements in the policy and regulatory areas were the IOTF’s development of the “exploratory IND” and oversight of the design and implementation of the ISPY-2 Trial through the FNIH-BC. She served for over 18 years as a senior scientist and subsequently as a senior executive in biomedicine at Battelle Memorial Institute; and co-founded and served as the CEO of a public (biotechnology) drug development company. As a volunteer, she has served in a number of capacities and led key programs for several government and professional organizations including the NCI, American Association for Cancer Research (AACR), C-Change, DOD Breast Cancer Program and many others. Dr. Barker has received a number of awards for her achievements in science and her advocacy for cancer research. Her research interests include complex adaptive systems (CAS), biomarker discovery and development, experimental therapeutics and free-radical biochemistry in cancer etiology and treatment. Dr. Barker completed her M.A. and Ph.D. at the Ohio State University, where she trained in immunology and microbiology.
José Baselga, M.D., Ph.D.
José Baselga, M.D., Ph.D. is an internationally recognized clinician and researcher, currently serving as Physician-in-Chief and Chief Medical Officer of Memorial Sloan Kettering Cancer Center, President of AACR and a past President of ESMO. His clinical interests focus on identifying novel mechanisms of resistance to current breast cancer therapies, while his laboratory work focuses on growth factor receptors and signaling pathways as targets for therapy. Dr. Baselga led the pivotal studies that showed efficacy of the HER family kinase inhibitors cetuximab, gefitinib and trastuzumab. His efforts resulted in the approval of pertuzumab and everolimus in breast cancer. He now leads clinical studies with PI3K inhibitors.

Robert M. Califf, M.D., MACC
Robert M. Califf, M.D., MACC, was named Deputy Commissioner for Medical Products and Tobacco for the Food and Drug Administration (FDA) in February of 2015. Dr. Califf provides executive leadership to the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, the Center for Devices and Radiological Health, and the Center for Tobacco Products. He also oversees the Office of Special Medical Programs and provides direction for cross-cutting clinical, scientific, and regulatory initiatives, including precision medicine, combination products, orphan drugs, pediatric therapeutics, and the advisory committee system.

Prior to joining the FDA, Dr. Califf was a professor of medicine and vice chancellor for clinical and translational research at Duke University. He also served as director of the Duke Translational Medicine Institute and founding director of the Duke Clinical Research Institute. A nationally and internationally recognized expert in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research, Dr. Califf has led many landmark clinical trials and is one of the most frequently cited authors in biomedical science, with more than 1,200 publications in the peer-reviewed literature.

Vijay Chandru, Ph.D.
Vijay Chandru, Ph.D., MIT ‘82 is an academic turned entrepreneur. His academic career in data science spanned over two decades as a professor first at Purdue University and then Indian Institute of Science. He is a fellow of the national academies of science and engineering in India. A Technology Pioneer of the World Economic Forum, Vijay serves on the WEF’s Global Agenda Council for the future of the health sector. As an entrepreneur, Vijay leads the new generation healthcare company Strand Life Sciences (US subsidiary Strand Genomics Inc.). Since 2007, Strand has been a global leader in bioinformatics products licensed to over 1400 research labs worldwide. With a team of over 250 high calibre scientists in India and the US, Strand is now leading the charge in clinical genomics and personalized medicine in India with over 100 partner hospitals and clinics. Strand’s proprietary, validated, “reads to reports” sequence alignment to clinical reporting platforms Strand NGS™ and StrandOmics™ address global market opportunities in precision medicine.
Sir John Chisholm

Sir John Chisholm began his career as a graduate apprentice with General Motors after graduating in Mechanical Sciences from Cambridge. Following this apprenticeship he joined the computing consultancy branch of BP named Sicon Ltd. He went on to found the start-up CAP Scientific Ltd., which grew rapidly while he was managing director. In 1991 he was appointed by the UK government to consolidate the UK Defence Research Establishments into one organization where he became instrumental in its launch into the commercial world as QinetiQ—soon after, he transitioned from holding the title of Chief Executive of QinetiQ to become the Chairman. He was also appointed as the Chairman of the National Endowment for Science Technology and the Arts. Chisholm is a fellow of the Royal Academy of Engineering, the Royal Aeronautical Society, the Institute of Physics, and is the immediate past President and Trustee of the Institution of Engineering & Technology and holds honorary Doctor of Engineering degrees from the Universities of Bath, Southampton and Brunel. More recently, he has employed his engineering background towards a career as a research administrator and served as Chairman of the Medical Research Council. Currently, he is the executive chair of a nonprofit company set up by the Department of Health in the UK called Genomics England, which aims to sequence thousands of whole genomes.

Francis S. Collins, M.D., Ph.D.

Francis S. Collins, M.D., Ph.D. is the Director of the National Institutes of Health (NIH). In that role he oversees the work of the largest supporter of biomedical research in the world, spanning the spectrum from basic to clinical research.

Dr. Collins is a physician-geneticist noted for his landmark discoveries of disease genes and his leadership of the international Human Genome Project, which culminated in April 2003 with the completion of a finished sequence of the human DNA instruction book. He served as director of the National Human Genome Research Institute at the NIH from 1993-2008.

Before coming to the NIH, Dr. Collins was a Howard Hughes Medical Institute investigator at the University of Michigan. He is an elected member of the Institute of Medicine and the National Academy of Sciences, was awarded the Presidential Medal of Freedom in November 2007, and received the National Medal of Science in 2009.

Christine Cournoyer

Christine Cournoyer is Chief Executive Officer of N-of-One. Prior to joining N-of-One, she was President and Chief Operating Officer of Picis (now a division of United Healthcare), a leading company in the healthcare IT market. Picis provides software solutions that bridge revenue cycle and clinical workflow management for high-acuity operations within hospitals, including emergency rooms, operating rooms, and critical care.

At the time of its acquisition, Picis’ systems were installed in more than 1,800 medical centers, hospitals, and integrated delivery networks in 19 countries around the world. Ms. Cournoyer served as President and Chief Operating Officer of Lightbridge, Inc. and held senior management positions at IBM, including Vice President of Business Transformation as well as Chief Information Officer of IBM’s software group. She also served as Senior Vice President at Lotus Development. Ms. Cournoyer was named one of the “10 Most Influential Women in Technology” by BusinessWeek. She is currently a Corporator for Emerson Hospital and a member of both the Boston Club and the Women Corporate Directors. Ms. Cournoyer earned a B.S. from UMass, Lowell and an M.A. in Economics from Northeastern University. She also attended Massachusetts Institute of Technology’s Executive Education Program.
**Mikael Dolsten, M.D., Ph.D.**

Mikael Dolsten, M.D., Ph.D. is President of Pfizer Worldwide Research and Development (WRD) and Executive Vice President of Pfizer Inc. He is focused on advancing the company’s pipeline and provides scientific leadership for all Pfizer products. Dr. Dolsten is a member of the Pfizer Executive Leadership Team and co-chairs the company’s Portfolio Strategy and Investment Committee, which governs major pipeline investments and strategic end-to-end R&D priorities.

Dr. Dolsten leads the WRD group at Pfizer, comprised of approximately 9000 R&D colleagues worldwide supporting Pfizer’s R&D projects and marketed products. He is responsible for all research at Pfizer, including development of compounds through proof of concept (POC) and provides safety, regulatory and clinical operations activities to all of Pfizer’s projects and marketed products. WRD is comprised of Pfizer’s research units and Pfizer’s partner lines. The research units include Cardiovascular and Metabolic/Renal Disease; Neuroscience and Pain; Oncology; Inflammation and Immunology; Vaccines; and Rare Disease, as well as the Centers for Therapeutic Innovation (CTI) and the biotech unit, Rinat. Mikael leads Pfizer’s partner line groups that oversee safety, regulatory, development operations, external R&D innovation, as well as science-based teams in biosimilars R&D, pharmaceutical sciences, drug safety R&D and design of small, large and vaccines therapies.

Prior to joining Pfizer in 2009, Dr. Dolsten was President of Wyeth Research responsible for global research and development activities. Before joining Wyeth, he served as Executive Vice President for Worldwide Research at Boehringer Ingelheim. His earlier career as a research leader included VP leadership positions with AstraZeneca, Pharmacia and Upjohn. Mikael has, during his 25 years in the Pharmaceutical industry, led R&D groups that have selected more than 100 Candidate drugs for treatment of human disease and supported the R&D advancement of some 20 important novel medicines and vaccines. Dr. Dolsten has also served as a Private Equity partner at Orbimed, the world’s largest healthcare focused investment company. In addition, he gained leadership experience from five large-scale M&A transactions.

Dr. Dolsten earned his Ph.D. in tumor immunology and M.D. from the University of Lund in Sweden. He studied virology and cell biology at the Weizmann Institute in Israel and has been appointed as Adjunct Professor in Immunology at the Medical Faculty in Lund, Sweden.

Mikael is a governor of the New York Academy of Sciences, a member of the board of Karyopharm Therapeutics Inc., a member of the Biomedical Advisory Council of The Pharmaceutical Research and Manufacturers of America (PhRMA), co-lead for the industry-NIH Accelerating Medicine Partnership (AMP) Executive Committee and serves on the PhRMA Foundation Board of Directors. He has been a board member of a Swedish Business School for Innovation and Chamber of Commerce. Dr. Dolsten is a named inventor on several patents and has published approximately 150 articles in international journals, with particular contributions in areas such as molecular cell biology, immunology and oncology.

**Lynn G. Dressler, Dr.P.H.**

Lynn Dressler, Dr.P.H. joined Mission Health, in February 2013, to develop and direct the Personalized Medicine and Pharmacogenomics Program. Mission Health is the only tertiary care hospital system in the mountains of Western North Carolina, the main referral hospital for a largely rural, underserved region of nearly 1 million residents. Formerly a faculty member in the Schools of Medicine and Pharmacy at the University of North Carolina at Chapel Hill, and a founding member of the UNC Institute for Pharmacogenomics and Individualized Therapy, Dressler’s 30 year career spans translational laboratory research in cancer, health policy research and the ethical and social implications of genomic medicine. Dressler holds a Master’s in Experimental Pathology, a doctorate in Health Policy and completed a fellowship in ELSI research. At UNC, her laboratory conducted the research study that directly led to the FDA approval of the HER2 FISH assay (PathVYsion ™), one of the first pharmacogenomic tests in solid tumors. In North Carolina, nearly 10 years prior to GINA, Dressler worked with the NC General Assembly to pass a law to prohibit discrimination by employers and health insurance providers on the basis of an individual’s genetic information. She has over 100 publications in related fields.

Working closely with NIH/NCI/NHGRI, Dressler has served in many leadership roles (External Advisor to TCGA study; NCI caHUB ethics working group, eMERGE Return of Results and Data sharing working groups; co Chair CALGB Correlative Sciences Committee). She currently serves as a member of the Clinical Pharmacogenomics Implementation Committee (CPIC); the Ethics and Policy Working Group of the NHGRI/NCI International Cancer Genome Consortium (ICGC) and a guest member of the Institute of Medicine’s Roundtable on Translating Genomic Findings to Improve Health.
Deborah Dunsire, M.D.

Deborah Dunsire, M.D. is an industry leader who brings more than 25 years of scientific, clinical, operational, and commercial experience, and proven leadership in the biotechnology and pharmaceutical industries. Prior to joining FORUM Pharmaceuticals in 2013, she served as President and Chief Executive Officer of Millennium Pharmaceuticals, Inc., now Millennium: The Takeda Oncology Company, from 2005 to 2013. During that period, she transformed the company into a biotechnology industry leader by focusing R&D, driving the development pipeline, fostering a culture of employee engagement, increasing the commercial mind-set across the organization, and crafting highly effective partnerships to drive the company’s growth. Millennium was acquired by Takeda Pharmaceutical Company Limited in 2008 for $8.8 billion, one of the largest biotech acquisitions at that time.

Deborah was the first woman appointed to the board of Takeda Pharmaceuticals Limited in Japan. Prior to this, Deborah led the Novartis Oncology Business in North America, playing a critical role in the broad development and successful launch of a number of products, increasing revenues from $50 million to more than $2.2 billion. Currently, Deborah is a board member of the Biotechnology Industry Organization (BIO). She is a trustee of the Museum of Science (Boston) and a member of the Massachusetts General Hospital Research Advisory Council. Until its sale to Actavis in March of 2015, Deborah was a long-standing board member of Allergan Pharmaceuticals. She has received numerous awards, including the 2001 American Cancer Society Excalibur Award; the 2009 Healthcare Businesswomen’s Association’s “Woman of the Year;” the 2011 MassBIO Innovator Award; and the 2013 Boston CEO Conference Lifetime Achievement Award.

Deborah received her medical degree from the University of Witwatersrand, Johannesburg, South Africa.

Richard Friedberg, M.D., Ph.D., FCAP

Richard Friedberg, M.D., Ph.D., FCAP, at Baystate Health, leads a hybrid academic/private practice group of 21 pathologists and a regional reference laboratory providing exclusive diagnostic services to 5 hospitals, numerous nursing homes, and more than 3300 providers across Massachusetts. He is also Professor and Deputy Chairman of the Department of Pathology, Tufts University School of Medicine.

Dr. Friedberg holds a Bachelor Science (BS) with Honors from Stanford University, an MD from Duke University, a PhD in coagulation biochemistry from Duke University, and a Master’s (SM) in Health Care Management from Harvard University. He is a Certified Physician Executive (CPE) by the American College of Physician Executives. Over the past 20 years, he has also served on numerous committees and councils for the College of American Pathologists (CAP), including the Government & Professional Affairs, Accreditation, Quality Practices, Technology Assessment, Transformation, Finance, & Transfusion Medicine. In 2007 and again in 2010, he was elected by the CAP membership to serve on the CAP Board of Governors. In 2013, the CAP membership elected him to serve as CAP President-Elect and will be CAP President from 2015-17.

Sean George, Ph.D.

Sean George, Ph.D. was co-founder and CEO of Locus Development, an early-stage genetic analysis startup. Prior to co-founding Locus, he served as the chief operating officer at Navigenics, an early leader in personalized medicine. He has also served as senior vice president of marketing at Affymetrix, senior vice president of life science business at Affymetrix, and vice president of labeling and detection business at Invitrogen. He has worked at McKinsey & Company and Molecular Probes as well. Dr. George holds a Bachelor of Science from UCLA with a major in molecular genetics, a Master of Science in molecular biology from University of California, Santa Barbara and a doctorate in molecular genetics from University of California, Santa Cruz.
Richard Hamermesh

Richard Hamermesh is a Senior Fellow at the Harvard Business School where he was formerly the MBA Class of 1961 Professor of Management Practice. Richard created and teaches the second-year MBA elective, Building Life Science Businesses. Previously, he was the Course Head for the required first year course, The Entrepreneurial Manager. In addition Richard participates in several HBS Executive Education programs.

Richard was the founding Faculty Chair of the HBS Healthcare Initiative and has been instrumental in expanding the role of healthcare in MBA education and faculty research. Today, over 10% of students enrolled at Harvard Business School are pursuing careers in healthcare. From 1987 to 2001, Richard was a co-founder and a Managing Partner of The Center for Executive Development, an executive education and development consulting firm. Prior to this, from 1976 to 1987, he was a member of the faculty of the Harvard Business School.

Richard is also an active investor and entrepreneur, having participated as a principal, director, and investor in the founding and early stages of over 20 organizations. These have included startups, leveraged buy-outs, industry roll-ups, and non-profit foundations. He was the founding president of the Newton (MA) Schools Foundation and served on the editorial board of the Harvard Business Review. Richard has served on numerous Boards of Directors, and has chaired the Audit Committees of two public companies. He is currently on the Boards of two public and two private corporations. From 1991 to 1996, he was the founding Chairman of Synthes Spine, Inc.

Richard is the author or co-author of five books, including New Business Ventures and the Entrepreneur. His best-known book, Fad-Free Management, was published in 1996. He has published numerous articles and more than 100 case studies. His most recent article, “Realizing the Potential of Personalized Medicine,” appeared in the Harvard Business Review (October 2007). Richard received his AB from the University of California, and his MBA and DBA from HBS. He is married, has two children, and four grandchildren. His hobbies include tennis, skiing, and yoga.

Xishan Hao, M.D., FACS

Prof. Xishan Hao, Academician of Chinese Academy of Engineering; Director of Tianjin Cancer Institute; Honorary President, Tianjin Medical University; Honorary President of Tianjin Medical University Cancer Institute & Hospital, He also serves as Vice President of Chinese Medical Association (CMA); President of Chinese Anti-Cancer Association (CACA); Board members of Union for International Cancer Control (UICC); Honorary Chairman, Asian Breast Cancer Society (ABCS); the Member of WHO International Agency for Cancer Registry (IACR) and Fellow of American College of Surgeons (FACS). He is Honorary Professor of Dundee University, UK, Honorary Professor of Fitchburg State College, U.S.A., Visiting Professor of Kurume University, Japan and Visiting Professor of Showa University, Japan. Editor-in-Chief of Chinese Journal of Clinical Oncology.

Robert Higgins

Robert Higgins is a co-founder of Causeway Media Partners and Highland Capital Partners. He is also a Senior Lecturer at Harvard Business School. He created and currently teaches a second year course called Entrepreneurship in Healthcare IT and Services (EHITS). Bob is Chairman of the Board of Advisors of NaviMed Capital and Waterline Ventures. He is also a member of the Harvard Faculty Committee for the MD/MBA program, the Harvard Medical School Health Care Policy Advisory Council and the Massachusetts General Hospital Research Advisory Council. In 2012, he was elected a fellow of the American Academy of Arts and Sciences.

Bob graduated from the Harvard Business School and Harvard College.
Paul Hudson

Paul Hudson is responsible for leading AstraZeneca’s commercial operations in North America and represents the region as a member of the Senior Executive Team. In this capacity he is accountable for driving growth and maximizing contribution of North America to AstraZeneca’s global business.

Prior to his role in North America, Paul served as Representative Director and President of AstraZeneca K.K., the Japanese subsidiary of AstraZeneca PLC. He has served as a Standing Board Member of JPMA (Japan Pharmaceuticals Manufacturers Association) and EFPIA (European Federation of Pharmaceutical Industries and Associations) in Japan.

Previously Paul was President of AstraZeneca’s business in Spain. He joined AstraZeneca in 2006 as Vice President and Primary Care Director, UK. Before AstraZeneca, Paul worked for Schering Plough, where he held roles of increasing seniority, including leading biologics global marketing, based in the US. He began his career at GSK UK and Sanofi-Synthelabo UK with roles in sales and marketing.

Mr. Hudson received his degree in Economics from Manchester Metropolitan University and his diploma in Marketing from Chartered Institute of Marketing, UK.

He is affiliated with BIO: Board of Directors; Healthcare Leadership Council: Member; and the Institute of Medicine: Member of the Value & Science Driven Health Care Roundtable.

Kathy Hudson, Ph.D.

Kathy L. Hudson, Ph.D., is the Deputy Director for Science, Outreach, and Policy at the National Institutes of Health (NIH). Dr. Hudson leads the science policy, legislation, communication, and outreach efforts of the NIH and serves as a senior advisor to the NIH director. She is responsible for creating major new strategic and scientific initiatives for NIH and is currently leading the planning and creation of the President’s Precision Medicine Initiative Cohort Program. Dr. Hudson was a key architect of the National Center for Advancing Translational Sciences and the NIH BRAIN Initiative. She directs the agency’s efforts to advance biomedical research through policy development, public and stakeholder communication and education, and innovative projects and partnerships.

Dr. Hudson’s professional experience includes serving as the NIH Chief of Staff; Acting Deputy Director of the National Center for Advancing Translational Sciences, NIH; the Assistant Director of the National Human Genome Research Institute, NIH; and the founder and Director of the Genetics and Public Policy Center at John Hopkins University. Also at Hopkins, Dr. Hudson was an Associate Professor in the Berman Institute of Bioethics, Institute of Genetic Medicine, and Department of Pediatrics.

Dr. Hudson holds a Ph.D. in Molecular Biology from the University of California at Berkeley, an M.S. in Microbiology from the University of Chicago, and a B.A. in Biology from Carleton College.

Taro Inada, Ph.D.

Taro Inada, Ph.D., is a general manager at the Tokyo-based Denka Co., Ltd. He joined the company after completing his graduate studies at Tohoku University. During his career, he held research positions including visiting posts for research on advanced battery material sciences at National Institute of Material Science (NIMS) and Tokyo Institute of Technology in Japan. He co-leads new business ventures, strategic alliances and corporate R&D management in promoting new business planning and development.

Dr. Inada is focused on advancing the company’s pipeline and providing scientific leadership for all Denka’s Life Science products particularly in the areas of next generation diagnostics and personalized medicine.
L. Patrick James, M.D.

L. Patrick James, M.D., is the Chief Clinical Officer, Health Plans and Policy, Medical Affairs and assumed this role in June, 2014. In this position Dr. James supports the medical organization of Quest Diagnostics through strong business and medical input. Prior to assuming this role, he served as Senior Medical Director for National Accounts and Senior Managing Director of the Kansas Business overseeing all business functions in a five-state region.

Before joining Quest Diagnostics, Dr. James served LabOne as Executive Vice President for Pathology and Laboratory Services. He spent nine years with Health Midwest, a 14 hospital integrated delivery system in Kansas City, as Medical Director of Hospital Integration where he led seven service lines including: lab, pharmacy, radiology, pulmonary, case management, registration and medical records, and rehab. Dr. James’ experience spans Research Medical Center, St. Joseph Hospital in Denver, Colorado, and National Naval Medical Center in Bethesda, Maryland.

Dr. James earned his medical degree with honors from St. Louis University. He performed his internship and residency training in anatomic and clinical pathology with board certification at the National Naval Medical Center and post-graduate training in cytopathology with board certification at Johns Hopkins Hospital. Dr. James has received his extensive leadership development training with the United States Navy and with positions of increasing responsibility in both for profit and not for profit organizations.

Dr. James and his wife, Victoria, live in Leawood, Kansas.

Elizabeth Karlson, M.D.

Elizabeth Karlson, M.D. is a rheumatologist and epidemiologist at Brigham and Women’s Hospital and Associate Professor of Medicine at Harvard Medical School. She is Director of the Rheumatic Disease Epidemiology Research Program for the Section of Clinical Sciences, Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Brigham and Women’s Hospital. She serves as co-Director for the Human Immunology Center at Brigham and Women’s Hospital. Dr. Karlson’s research interests are in rheumatic disease epidemiology and outcomes, genetics, gene-environment interactions, and bioinformatics analysis of electronic health records for clinical and translational research. She is funded by the National Institutes of Health and has a Mid-Career Investigator Award to support mentoring and teaching of rheumatology fellows and junior faculty. Dr. Karlson serves as Co-Investigator, Phenotyping Center Director, and member of the Executive Committee for the Partners HealthCare Biobank that aims to collect samples, family history, lifestyle and environmental survey data linked with comprehensive health information from the electronic health record from 100,000 Partners HealthCare patients. She serves on the Advisory Council on Biology and Medicine, Alpert Medical School, Brown University. She has served on grant review committees for the National Institutes of Health, Arthritis Foundation, and national grant agencies in Canada and Europe. She has served on the American College of Rheumatology Blue Ribbon Panel on Academic Rheumatology. She has received the Henry Kunkel Young Investigator Award from the American College of Rheumatology, and the Senior Faculty Mentoring Award from the Brigham and Women’s Hospital.

Raju Kucherlapati, Ph.D.

Raju Kucherlapati, Ph.D. is the Paul C. Cabot Professor in the Harvard Medical School Department of Genetics. He is also a professor in the Department of Medicine at Brigham and Women’s Hospital. Dr. Kucherlapati was the first Scientific Director of the Harvard Medical School-Partners Healthcare Center for Genetics and Genomics. His research focuses on gene mapping, gene modification, and cloning disease genes. During 1989-2001, Dr. Kucherlapati was the Lola and Saul Kramer Professor of Molecular Genetics and Chairman of the Department of Molecular Genetics at the Albert Einstein College of Medicine in New York. He was previously a professor in the Department of Genetics at the University of Illinois, College of Medicine. He began his research as an assistant professor in the Department of Biochemical Sciences at Princeton University.

He has chaired numerous NIH committees and served on the National Advisory Council for Human Genome Research and the NCI Mouse Models for Human Cancer Consortium. He is also a member of the Cancer Genome Atlas project of the National Institutes of Health. He is a member of the Institute of Medicine of the National Academy of Sciences and a fellow of the American Association for the Advancement of Science. He is a member of Presidential Commission for the Study of Bioethical Issues.

Dr. Kucherlapati received his B.S. and M.S. in Biology from universities in India, and he received his Ph.D. from the University of Illinois at Urbana, as well as conducting post-doctoral work at Yale University.
**Speakers**

**David Ledbetter, Ph.D., FACMG**

David H. Ledbetter, Ph.D., FACMG, is Executive Vice President and Chief Scientific Officer at Geisinger Health System, a large, not-for-profit integrated health system in Danville, PA. Dr. Ledbetter came to Geisinger from Emory University School of Medicine in Atlanta where he was the Robert W. Woodruff Professor and Director of the Division of Medical Genetics in the Department of Human Genetics. He previously held academic and leadership positions at the University of Chicago, the National Center for Human Genome Research (now NHGRI) at the National Institutes of Health and Baylor College of Medicine. He is a graduate of Tulane University and earned his doctorate at the University of Texas-Austin. After his early discovery of the genetic causes of Prader-Willi syndrome and then Miller-Dieker syndrome, Dr. Ledbetter has focused his research efforts on discovering the underlying etiology of childhood developmental disabilities such as autism, and the translation of new genomics technologies into clinically useful genetic tests for early diagnosis and intervention. His current research interest includes leveraging the massive amount of genomics data generated during routine patient care for knowledge generation and integration of this information into electronic health records in a clinically useful manner. Dr. Ledbetter has been a strong advocate of genomic data sharing to accelerate knowledge and improved patient care, and served as a plaintiff in the recent Supreme Court case, Association for Molecular Pathology v. Myriad Genetics (June 13, 2013), which overturned the patentability of human genes and will now allow increased access and improved quality of genetic testing in the United States.

**Mark Levin**

Mark Levin is a co-founder of Third Rock Ventures and an industry leader with 40 years of experience, including more than 30 years launching and building biotechnology companies. Mark focuses on the formation, development and business strategy of our portfolio companies, as well as actively identifying and evaluating new investments. He runs our discovery process to conceive and launch companies around disruptive technologies and innovative science that promise to dramatically improve patients’ lives. He has played significant roles in launching and building a number of our portfolio companies: board member and former interim CEO of Voyager Therapeutics; board member of DC Devices; board member of NinePoint Medical and former interim CEO; board member of Warp Drive Bio; board member and former interim CEO of Eleven Biotherapeutics; Former board member of Foundation Medicine.

Prior to Third Rock, Mark was co-founder of Mayfield Fund’s life sciences effort, where he was also the founding chief executive officer of Tularik, Cell Genesys/Abgenix, Focal, Stem Cells and Millennium Pharmaceuticals. Mark served as chief executive officer of Millennium Pharmaceuticals for 12 years. Earlier in his career, he was an engineer and project leader at Lilly and Genentech. Mark holds an M.S. in chemical and biochemical engineering from Washington University.
James Madara, M.D.

James L. Madara, M.D. is CEO of the American Medical Association. The AMA is the largest physicians organization and has as its mission: “to promote the art and science of medicine and the betterment of public health”. Toward this end the AMA publishes 10 journals (the JAMA network including JAMA – the widest circulating general medicine journal worldwide), has multiple business products aimed at practicing physicians as well as business-to-business, convenes the nations 185 medical societies, curates the nations procedural code-sets used for billing (CPT), produces the majority of clinical quality measures used by the federal government, and maintains the nations master-file of American physicians. The long range strategic plan, established after Dr. Madara’s arrival, has three focus areas: improving patient outcomes, restructuring medical education to match the evolving needs of our health system, and defining and disseminating the operational characteristics which promote practice satisfaction and sustainability.

Dr. Madara spent the first 22 years of his career at Harvard Medical School (HMS), completing his clinical training in Pathology, research training in Cell Biology and Physiology, and ultimately serving as Professor of Pathology (Brigham and Women’s Hospital) and Director of the Harvard Digestive Disease Center – a NIH P-30 Center. After HMS, Dr. Madara served for five years at Emory University as the Timmie Professor and Chairman of the Department of Pathology and Laboratory Medicine. In 2002 Dr. Madara was appointed as Dean of the Pritzker School of Medicine and Dean of Biological Sciences covering both the College and the Graduate Programs at University of Chicago. There he served as the Thompson Distinguished Service Professor and had the added responsibility of CEO of the University of Chicago Medical Center and Hospitals.

In his academic career Dr. Madara functioned in several capacities including: Editor-in-Chief of the American Journal of Pathology; Chairman of the NIH General Medicine A-2 Study Section; and President of the American Board of Pathology. He has also been recognized as: a Fogarty International Scholar at the Institute Pasteur, Paris; an elected member of the Association of American Physicians; a member of the IOM Roundtable on Value and Science-Driven Healthcare; recipient of a MERIT Award from the NIH; recipient of the Astra Zeneca International Prize for Distinguished Research in Digestive Disease; recipient of the Horace Davenport Lifetime Achievement Award for GI Physiology by the American Physiological Society; and recipient of honorary degrees from several institutions.

Dr. Madara has served or is serving in governance of the following organizations: Board of Research!American; Greater Chicagoland Chamber of Commerce; Board of National Opinion Research Center (NORC); External Advisory Committees, Stanford Medical School and University of Pittsburgh School of Medicine; Commercial Club of Chicago.
Barbara McAneny, M.D.

Barbara L. McAneny, M.D., a board-certified medical oncologist/hematologist from Albuquerque, N.M., was re-elected to the American Medical Association Board of Trustees in June 2014. Her many leadership roles have included president of the New Mexico Medical Society (NMMS), president of the Greater Albuquerque Medical Association, and president of the New Mexico Chapter of the American College of Physicians.

She became the delegate to the AMA from the American Society of Clinical Oncology (ASCO) in 2002, and was elected to the AMA Council of Medical Service in 2003, serving as its chair in 2009–2010. She has also served on several ASCO committees and the ASCO Board of Directors. She is a member of the Community Oncology Alliance Board of Trustees. Dr. McAneny was appointed by Health and Human Services Secretary Tommy Thompson to the Practicing Physicians Advisory Council from 2002 to 2006. She was a founding member of Oncology Circle, an organization of oncology practices using data to promote best practices. She has served on the board of directors of the Cancer Center Business Summit. She has championed numerous health-related issues including tobacco-use prevention, professional liability reform and emergency medical services (EMS).

In 2012 Dr. McAneny received a $19.8 million award from the Centers for Medicare & Medicaid Innovation to test how oncology private practices can provide cancer patients better care at a lower cost.

Among other volunteer activities, she has served on the governor of New Mexico’s Task Force on Prenatal Care, the board of Planned Parenthood of New Mexico, and as chair of the joint task force of the NMMS and the New Mexico Bar Association on domestic violence. A recipient of a New Mexico Woman on the Move Award in 2005 and Woman of Influence Award in 2009, Dr. McAneny has been voted several times by her peers as Albuquerque The Magazine’s “Top Doc” in her specialty, including 2014. She co-founded New Mexico Oncology Hematology Consultants Ltd. in 1987. A managing partner since 1999, she built New Mexico Cancer Center, which provides comprehensive outpatient medical and radiation oncology care and imaging at multiple sites, including several underserved rural areas. She also founded the New Mexico Cancer Center Foundation, which provides grants to patients to help with their nonmedical expenses.

Dr. McAneny graduated magna cum laude from the University of Minnesota in 1973 and with honors from the University of Iowa College of Medicine in 1977. She completed her residency in internal medicine at the University of Iowa in 1980 and her fellowship in hematology/oncology at the University of New Mexico in 2003.

She is married to Steven P. Kanig, MD, a nephrologist who presently focuses on informatics and serves as vice chair of the board of New Mexico’s health information exchange. Dr. Kanig also serves as a delegate to the AMA for New Mexico.

Cynthia Casson Morton, Ph.D.

Cynthia Casson Morton, Ph.D. received her Bachelor of Science degree from the College of William and Mary in Virginia and her Ph.D. in Human Genetics from the Medical College of Virginia in Richmond. She is the William Lambert Richardson Professor of Obstetrics, Gynecology and Reproductive Biology and Professor of Pathology at Harvard Medical School, Director of Cytogenetics and Past Director of the Biomedical Research Institute at Brigham and Women’s Hospital. She is an Institute Member of the Broad Institute of MIT and Harvard. Dr. Morton is an adjunct faculty member of the University of Manchester where she holds a position as Chair in Auditory Genetics. Dr. Morton is certified by the American Board of Medical Genetics in Ph.D. Medical Genetics, Clinical Cytogenetics and Clinical Molecular Genetics. Her research interests are in molecular cytogenetics, hereditary deafness, genetics of uterine leiomyomata and human developmental disorders. She has published over 275 original articles.

Dr. Morton is a past member of the Board of Directors of the American Board of Medical Genetics where she served as Secretary, Treasurer and Chair of the Accreditation Committee. She was the Chair of the Molecular Genetic Pathology Policy and Exam Committees of the American Board of Medical Genetics and the American Board of Pathology. She served as Member and Chair of the Board of Scientific Counselors of the National Institute of Deafness and Other Communication Disorders, and as Member and Chair of the Board of Regents of the National Library of Medicine. Dr. Morton is currently a member of the Counsel of Scientific Trustees of the Hearing Health Foundation, and Chair of the Veteran’s Administration Genomic Medicine Program Advisory Committee. Dr. Morton is a member of the Board of Directors of the American Society of Human Genetics and served as the 2014 President. She recently completed a six year tenure as Editor of The American Journal of Human Genetics and is currently Co-Editor of Human Genetics.
John Niederhuber, M.D.

John E. Niederhuber, M.D., is Director Emeritus of the National Cancer Institute of the National Institutes of Health and is presently an Executive Vice President of the Inova Health System and CEO of the Inova Translational Medicine Institute (ITMI). Dr. Niederhuber is also Adjunct Professor of Oncology and Surgery at the Johns Hopkins University School of Medicine and serves as Deputy-Director of the Johns Hopkins Clinical Research Network. A nationally renowned surgeon and researcher, Dr. Niederhuber has dedicated his career to the treatment and study of cancer. As a university professor, he held many administrative positions, including Department Chair, Associate Dean for Research, Senior Associate Dean for Academic Affairs, and NCI-designated cancer center director. Dr. Niederhuber served as chair of the National Cancer Advisory Board, external advisor to the NCI, and has been a laboratory investigator supported by NCI and the NIH. He is the Senior Editor and a contributing author of the fifth edition of the textbook Abeloff’s Clinical Oncology. Dr. Niederhuber is a member of the Institute of Medicine, National Academy of Sciences, and a Fellow of the American Association for the Advancement of Science.

Gary Palmer, M.D., J.D., M.B.A., M.P.H.

Gary Palmer, M.D., J.D., M.B.A., M.P.H. is the Chief Medical Officer at Nanthealth. Previously, he was the Senior Vice President, Medical Affairs, at Foundation Medicine. He is a veteran of the pharma and biotech industry. Before Foundation Medicine, he was Vice President of Medical Affairs at Genomic Health where he directed the medical aspects of the Oncotype DX Breast Cancer Assay. After Genomic Health, he served as Chief Medical Officer of On-Q-ity, a circulating tumor cell company. Prior to Genomic Health, Dr. Palmer had extensive experience in the pharmaceutical industry, including roles as Executive Director at Kosan Biosciences and at Salmedix, Inc. where he spent time in early drug development. Previously, he spent five years at Amgen where he was involved in the development and commercialization strategies of Neulasta and Aranesp.

Before his roles in industry, Dr. Palmer served as a medical oncologist in both academia and in the community setting. Dr. Palmer was director of the Medical Breast Service at the University of California, Davis, Cancer Center and Chief of Medical Oncology at the Mercy Health System, Sacramento, California. For nine years he was on the adjunct faculty of the University of California, Davis, Graduate School of Management where he taught “Management of Biotechnology” to MBA students. Dr. Palmer is a magna cum laude graduate of Yale University and a graduate of the Stanford University School of Medicine. He did his internal medicine training at the Boston City Hospital and his oncology fellowship at the Massachusetts General Hospital. He has a Masters in Business Administration (MBA) from the University of California, Davis, and a Masters in Public Health (MPH) from U.C.L.A. As well, Dr. Palmer holds a J.D. degree and is admitted as an attorney to the State Bar of California.

Michael Pellini, M.D., M.B.A.

Michael Pellini, M.D., M.B.A. joined Foundation Medicine as President and Chief Executive Officer in May 2011, bringing a breadth of experience in life sciences and the clinical diagnostics and laboratory industries to the company. Dr. Pellini came to Foundation Medicine from Clariant, a GE Healthcare Company, where he held the position of President and Chief Operating Officer. Dr. Pellini joined GE Healthcare through the integration of Clariant, Inc., where he worked with the company’s leadership team to drive operational excellence and reimbursement strategies in parallel with the development and commercialization of multiple diagnostic tests. Dr. Pellini’s leadership was instrumental in building Clariant to the highly successful acquisition by GE Healthcare in October 2010.

Prior to his tenure with Clariant, Dr. Pellini served as Vice President, Life Sciences at Safeguard Sciences, Inc. where he leveraged his business and medical expertise to explore new market opportunities and to support Safeguard’s partner companies. Prior to Safeguard, he was Executive Vice President and Chief Operating Officer at Lakewood Pathology Associates, a national molecular pathology services company, which was acquired by Water Street Healthcare Partners in 2006. Previously, Dr. Pellini was an Entrepreneur-in-Residence at BioAdvance, where he was responsible for identifying early-stage life science opportunities. He also served as President and Chief Executive Officer of Genomics Collaborative, Inc., a Boston-based biotech firm that was acquired by SeraCare Life Sciences, Inc. in 2004.

Dr. Pellini received a BA from Boston College, an MBA from Drexel University and an MD from Jefferson Medical College of Thomas Jefferson University. He is a board member of the Personalized Medicine Coalition and serves on the President’s Leadership Council of Jefferson Medical College.
Kimberly Popovits

Kimberly Popovits, committed to changing the paradigm of cancer care, has led Genomic Health in revolutionizing the treatment of cancer through genomic-based diagnostic tests for breast, colon and prostate cancers that address the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. Kim has served as Genomic Health’s Chairman of the Board since 2012, and Chief Executive Officer and President since 2009. She was President and Chief Operating Officer since joining the company in 2002. Prior to joining Genomic Health, Kim served as Senior Vice President, Marketing and Sales at the biotechnology company, Genentech, Inc. During her 15 years at Genentech, Kim led the successful commercialization of 14 new therapies, including Herceptin®, the revolutionary targeted treatment that changed the way doctors treat a particularly aggressive form of breast cancer. Before joining Genentech, Kim served as division manager for American Critical Care, a division of American Hospital Supply Corporation. Kim currently serves on the boards of the California Life Sciences Association (CLSA), the Personalized Medicine Coalition (PMC), the American Clinical Laboratory Association (ACLA), and ZS Pharma. Kim is also the President of The Coalition for 21st Century Medicine, and serves as an Advisor to the Healthcare Businesswomen’s Association (HBA). Kim’s contributions to science and the commercialization of the biotechnology industry have been acknowledged by multiple organizations including being named Most Admired CEO in 2014 as well as one of the Most Influential Women in the Bay Area from 2006-2012 by the San Francisco Business Times. She was also named Woman of the Year in 2008 by the Women Health Care Executives. Kim holds a Bachelor of Arts degree in Business from Michigan State University.

Michael Reitermann

Michael Reitermann assumed the role of CEO, Siemens Healthcare Diagnostics Inc. on May 1, 2010. In this position, Mr. Reitermann is responsible for the Siemens Healthcare Diagnostics division. Mr. Reitermann is based in Tarrytown, NY.

Mr. Reitermann’s passion for science and technology has driven his extensive career with Siemens. In his previous role he was responsible for the U.S. imaging organization. Before that assignment, he served as CEO of the Siemens Molecular Imaging Business Unit. Mr. Reitermann was responsible for the establishment and implementation of the Molecular Imaging’s business objectives around the world, as well as the Business Unit’s overall financial performance. During his tenure, Siemens launched the Symbia, Biograph Truepoint and Biograph mCT product lines.

Reitermann has enjoyed a long career with Siemens, including serving as vice president for sales, marketing and innovation of the Siemens Angiography and X-ray Division (AX). In this position, Reitermann was responsible for product definition and worldwide marketing and promotion of Siemens AX products, including the successful AXIOM product line. From 1996 to 1998, he also served as a partner in Siemens Management Consulting, conducting consulting projects in the areas of benchmarking, strategy and productivity. Prior to 1996, Reitermann worked as a consultant, then a senior project manager at the corporate strategies division of Siemens Corporate Planning and Development.

Educated at Hans-Grueninger-Gymnasium in Markgroeningen, Germany, Reitermann received a graduate degree in industrial engineering from the University of Karlsruhe, Germany, and a master’s of business administration from the University of British Columbia, Canada.

Jonathan Sheldon, Ph.D.

Jonathan Sheldon, Ph.D., is Global Vice President Healthcare responsible for Oracle Health Sciences healthcare analytics platform and solutions including in the areas of translational medicine, population health and convergence with Life Sciences. Previously, Dr. Sheldon was Chief Scientific Officer at InforSense, where he was responsible for the company’s strategic direction in the health sciences market, as well as leading the consulting group. Prior to InforSense, he was Chief Technology Officer for Confirmant Ltd, where he was responsible for developing the company’s proteomics products and services. He also established the first bioinformatics group and was Head of Bioinformatics for five years at Roche Welwyn, UK.

Dr. Sheldon holds a Ph.D. in Molecular Biology/Biochemistry from the University of Cambridge.
Sue Siegel

Sue Siegel leads two of GE’s growth and innovation initiatives as CEO, GE Ventures & healthymagination. GE Ventures invests in and partners with the start-up ecosystem across Healthcare, Energy, Software, and Advanced Manufacturing. Healthymagination harnesses innovation and partnership inside and outside GE to improve the quality, access and affordability of healthcare.

Sue has more than 30 years of experience in corporate and venture capital. Previously, as a financial VC, Sue led investments in personalized medicine, digital health, and life sciences at Silicon Valley-based Mohr Davidow Ventures. Before venture capital, she drove strategy and technology development as well as new market growth at Bio-Rad, DuPont, Amersham, and Affymetrix (NASDAQ: AFFX). As President and a Board Member of Affymetrix, Sue led the company’s transformation from a pre-revenue start up to a global, multi-billion dollar market cap genomics leader.

Sue has served on over two dozen private and public corporate boards. She currently serves on the Boards of: the National Venture Capital Association, Stanford Hospital Board’s IT Committee, Harvard Partners’ Innovation Advisory Board, the Cleveland Clinic’s Innovation Council, University of California’s Innovation Council, and serves on the Executive Committee of Santa Clara University’s Center for Science, Technology, and Society’s Advisory Board. She is a President’s Circle member of the National Academies of Science, a member of YPO-WPO, Women Corporate Directors, and a Henry Crown Fellow of the Aspen Institute. In the bestselling business book: Multipliers: How The Best Leaders Make Everyone Smarter, Sue was a featured “Multiplier”. She was recognized as one of “The 100 Most Influential Women in Silicon Valley”.

Sue lives in Silicon Valley with her husband and her two sons. When not working, you might find her hiking the scenic trails of Northern California.

Ralph Snyderman, M.D.

Ralph Snyderman, M.D. is Chancellor Emeritus, Duke University and James B. Duke Professor of Medicine in the Duke University School of Medicine. He served as Chancellor for Health Affairs and Dean of the School of Medicine at Duke University from 1989 to July 2004 and led the transition of this excellent medical center into an internationally recognized leader of academic medicine. He oversaw the development of the Duke University Health System, one of the most successful integrated academic health systems in the country, and served as its first President and Chief Executive Officer. Dr. Snyderman has played a leading role in the conception and development of Personalized Health Care, an evolving model of national health care delivery.

He was amongst the first to envision and articulate the need to move the current focus of health care from the treatment of disease-events to personalized, predictive, preventive, and participatory care that is focused on the patient. In 2012, he received the David E. Rogers Award from the Association of American Medical Colleges who referred to Snyderman as the “father of personalized medicine.” Dr. Snyderman is the recipient of numerous scientific and leadership awards recognizing his contributions to research and to developing more rational models of health care.

Dr. Snyderman has played a prominent role in the leadership of such important national organizations as the Association of American Physicians, the Institute of Medicine and the Association of American Medical Colleges. He is a member of the Institute of Medicine and the American Academy of Arts & Sciences. His bibliography includes nearly 400 manuscripts and numerous books. Snyderman received his M.D., magna cum laude, in 1965 from the Downstate Medical Center of the State University of New York. He served his internship and residency in medicine at Duke and later worked as a Public Health Officer doing research in immunology at the NIH (1967-72). He joined the faculty of the Department of Medicine at Duke University in 1972 and rose to the level of the Frederic M. Hanes of Medicine and Chief of the Division of Rheumatology. In 1987, Snyderman joined Genentech, Inc. where he was Senior Vice President for Medical Research and Development until returning to Duke as Chancellor for Health Affairs.
Speakers

Nahid Turan, Ph.D.
Nahid Turan, Ph.D., is principal investigator at Coriell Institute for Medical Research for the NIGMS Human Genetic Cell Repository, an extensive collection of more than 11,300 cell lines and 5,700 DNA samples representing a variety of disease states, chromosomal abnormalities and healthy individuals across several distinct human populations. In this role, Dr. Turan oversees all aspects of the NIGMS Repository management, coordinating with investigators and project managers to facilitate the daily operations of the repository, adopting new process efficiency measures, recruiting new samples, identifying new directions for the repository, and interfacing with governmental project officers and scientific advisory committee members. Dr. Turan is also principal investigator for the Congenital Heart Disease Genetic Network Study (CHD GENES) Biorepository at Coriell, which is funded through the National Heart, Lung, and Blood Institute (NHLBI).

Dr. Turan earned her Bachelor of Science degree in Biochemistry, Masters degree in Toxicology, and Doctorate in Biochemistry and Molecular Biology from the University of Birmingham in the United Kingdom. Dr. Turan has extensive experience in biorepository management and over seven years postdoctoral experience in epigenetics and molecular biology. Dr. Turan is also an Adjunct Assistant Professor of Biomedical Sciences in the Department of Biomedical Sciences at Cooper Medical School of Rowan University.

Jack Wang
Jack Wang is an inventor, entrepreneur and investor. He is currently the CEO & Founder of Biomobie, a revolutionary bioelectronic technology company with its R&D center based in Silicon Valley and 6 noninvasive angiogenesis centers based in Shanghai, Beijing, Nanjing and Chengdu, China.

Scott Weiss, M.D., M.S.
Scott Weiss, M.D., M.S. is currently Director of the Partners HealthCare Personalized Medicine. He is responsible for 12 faculty and approximately 100 staff that work in the Center’s Core Laboratories, the CLIA-approved Laboratory for Molecular Medicine, and the IT and Educational programs across the Partners HealthCare System. He is also the co-leader of the Systems Genetics and Genomics Unit in the Channing Division of Network Medicine in the Department of Medicine at Brigham and Women’s Hospital, and Professor of Medicine at Harvard Medical School. In this capacity, he co-leads a 30-investigator, 110-person research group involved in examining the environmental exposures and genetic risk factors for the development of asthma and chronic obstructive pulmonary disease (COPD). He has mentored 39 trainees over the past 27 years, all but two still remain in academia. He has authored or co-authored over 700 papers and co-written and co-edited four books, including a comprehensive textbook on Respiratory Genetics. His long-standing research interests have been in the area of environmental and genetic risk factors for the development of asthma and COPD. His initial work concerned the role of environmental tobacco smoke exposure in the development of asthma. He then studied the effect of airway responsiveness in populations on the development and natural history of asthma and COPD development. Through this work, he became interested in the overlap of asthma and COPD as complex diseases. In 1996, he developed a strong interest in the genetics/genomics of asthma. By 2000, he was fully funded to perform research in this area and now devotes most of his research time to asthma genetics/genomics. He has been continuously funded by NHLBI for 30 years and was identified as being in the top .01% of biomedical researchers in terms of scientific impact (Boyack, et al. Eur J Clin Invest. 2013; PMID: 24134636).
George D. Yancopoulos, M.D., Ph.D.

George D. Yancopoulos, M.D., Ph.D., joined Regeneron in 1989 as its Scientific Founder and is currently the Chief Scientific Officer and President of Regeneron Laboratories. He received his M.D. and Ph.D. in Biochemistry and Molecular Biophysics from Columbia University. In the 1990s, Dr. Yancopoulos was the 11th most highly cited scientist in the world, and in 2004 he was elected to both the National Academy of Sciences and the American Academy of Sciences. Dr. Yancopoulos, together with key members of his team, is a principal inventor and developer of Regeneron’s four FDA-approved drugs – PRALUENT® (alirocumab) Injection, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection - as well as of Regeneron’s foundational technologies for target and drug development, such as its proprietary TRAP technology, VelociGene® and VelocImmune®. These technologies have produced Regeneron’s robust pipeline of fully human antibodies targeting eye disease, cardiovascular disease, asthma and other allergic diseases, inflammatory conditions and cancer. In 2014, Dr. Yancopoulos and his team launched the Regeneron Genetics Center, a major new initiative in human genetic research.
About Us

Partners Healthcare Personalized Medicine

The Partners HealthCare Personalized Medicine (PPM) was launched in 2001 as the Harvard Medical School-Partners HealthCare Center for Genetics and Genomics. Its purposes from its founding have been to promote genetics and genomics in research and clinical medicine and to help realize the promise of personalized medicine by accelerating the integration of genetic knowledge into clinical care throughout the Partners HealthCare System (PHS) and in healthcare nationally and globally. PPM is accomplishing its mission by supporting and facilitating:

• pursuing important discoveries that will enable advancing the knowledge of how genetics affects human health and disease
• offering genetic-based diagnostic testing and developing new tests through a CLIA- and state-approved Laboratory for Molecular Medicine
• developing an IT infrastructure to integrate genetic and genomic data into clinical decision support systems
• educating practicing clinicians, investigators, health care professionals
• developing a program in Personalized/Predictive Medicine

Personalized medicine is the ability to determine an individual’s unique molecular characteristics and to use those genetic distinctions to diagnose more finely an individual’s disease, select treatments that increase the chances of a successful outcome and reduce possible adverse reactions. Personalized medicine also is the ability to predict an individual’s susceptibility to diseases and thus to try to shape steps that may help avoid or reduce the extent to which an individual will experience a disease.

For personalized medicine to be a fully functioning reality at the clinical level, certain elements are essential: an electronic medical record, personalized genomic data available for clinical use, physician access to electronic decision support tools, a personalized health plan, personalized treatments, and personal clinical information available for research use. Partners HealthCare has made a firm commitment to the principles of personalized medicine and to the importance of genetics and genomics in delivering the best care of patients. PHS also has committed to ensuring that the features above are or will be available.

The essential feature of the revolution in genetics and genomics has been an explosion in the amount of data available for use in translational research. This massive data profusion has enhanced our ability to predict both clinical phenotypes and clinical outcomes on the basis of genome scale data. In order to be able to do such predictions, the investigators will need several tools. First, a robust bioinformatics infrastructure that includes secure pipelines and algorithms for data cleaning and manipulation. Second, they will need strong bioinformatics platforms for data analysis and data management. Third, they need access to large numbers of very well phenotyped patients. Fourth, access to the genomic platforms to create genomic scale data on these patients for prediction of clinical outcomes and finally, they need novel statistical and bioinformatics methods to analyze data for predictive medicine. PPM makes all of these resources available to Partners investigators through a highly developed infrastructure consisting of bioinformatics and genetic statistics team, biobank, translational genomic core and an information technology team.

For more information about PPM, please visit http://personalizedmedicine.partners.org.
Harvard Business School

Harvard Business School’s mission is to train business leaders in all industries. Healthcare, a $2 trillion industry, has become one of the school’s key priorities. The Healthcare Initiative at HBS was launched in 2005 to bring together the extensive research, thought leadership, and interest in the business and management of healthcare that exists at HBS.

Healthcare research at HBS focuses on entrepreneurship, innovation and disruption. Faculty and students seek to understand and identify new products, services and delivery methods that will help to reshape the industry. HBS believes this focus on “creative destruction” will result in business models that offer the hope of improved outcomes, reduced costs, streamlined systems, and enhanced services.

Personalized medicine presents tremendous opportunities in healthcare and has garnered much attention at HBS. With its expertise in technology, commercialization, and business model development, HBS can play a critical role in the widespread adoption of personalized medicine applications.

For more information about the HBS Healthcare Initiative, please visit www.hbs.edu/healthcare.
Organizing Committee

Raju Kucherlapati, Ph.D., Co-Chair
Paul C. Cabot Professor of Genetics, Professor of Medicine
Harvard Medical School

Scott Weiss, M.D., M.S., Co-Chair
Director, Partners HealthCare Personalized Medicine
Professor of Medicine, Harvard Medical School
Channing Laboratories

Amy Abernethy, M.D., Ph.D.
Professor, Duke University School of Medicine
Chief Medical Officer and Senior Vice President of Oncology,
Flatiron Health, Inc.

Edward Abrahams, Ph.D.
President
Personalized Medicine Coalition

Joanne Armstrong, M.D., M.P.H.
Senior Director
Aetna, Inc.

Sujuan Ba, Ph.D.
COO, National Foundation for Cancer Research

Anna Barker, Ph.D.
Co-Director, Complex Adaptive Systems Initiative
Director, National Biomarker Development Alliance
Professor, School of Life Sciences, Arizona State University

Jennifer Cosenza
Senior Vice President
Feinstein Kean Healthcare | An Ogilvy Company

William Dalton, Ph.D., M.D.
CEO, M2Gen
Director, The DeBartolo Family Personalized Medicine
Institute at Moffitt Cancer Center

Gregory Downing, Ph.D.
Program Director, Personalized Health Care Initiative
Office of the Secretary
The U.S. Department of Health and Human Services

Stephen Eck, M.D., Ph.D.
Vice President, Global Head of Medical Oncology
Astellas Pharma Global Development, Inc.

Margaret Foti, Ph.D., M.D. (h.c.)
Chief Executive Officer
American Association for Cancer Research (AACR)

Robert C. Green, MD, MPH
Director, G2P Research Program
Associate Director for Research, Partners Personalized Medicine
Division of Genetics, Department of Medicine
Brigham and Women’s Hospital, Broad Institute and
Harvard Medical School

Robert Huckman, Ph.D.
Albert J. Weatherhead III Professor of Business Administration
Faculty Co-Chair, Health Care Initiative
Harvard Business School

Marcia A. Kean
Chairman, Strategic Initiatives
Feinstein Kean Healthcare

Jeffrey Leerink
Chairman and CEO, Leerink Partners LLC

Gerald J. McDougall
Partner, PricewaterhouseCoopers

Amy Miller, Ph.D.
Vice President, Public Policy, Personalized Medicine Coalition

Thomas Miller
Founder, GreyBird Ventures

Cynthia Morton, Ph.D.
William Lambert Richardson Professor of OB/Gyn and
Reproductive Biology and Professor of Pathology,
Harvard Medical School
Director of Cytogenetics, Brigham and Women’s Hospital

Hakan Sakul, Ph.D.
Executive Director, Head of Diagnostics
Worldwide R&D, Clinical Research and Precision Medicine
Pfizer Inc.

Jared N. Schwartz, M.D., Ph.D.
Independent HealthCare Consultant

Risa Stack, Ph.D.
General Manager, Emerging Health Innovations
GE Healthymagination

Katherine Johansen Taber, Ph.D.
Director, Personalized Medicine
American Medical Association

Robert Tepper, M.D.
Third Rock Ventures

Partners HealthCare Personalized Medicine Contacts

Janice Larson
Partners HealthCare Personalized Medicine

Amy McGlinn
Partners HealthCare Personalized Medicine
STRONG IDEAS NEED STRONG GLOBAL PARTNERS TO UNLEASH THEIR POTENTIAL.

GE Ventures provides small businesses, startups, and entrepreneurs with access to its global network of business units, partners and customers, and to its world-class training resources. All working to identify, scale and accelerate ideas that can advance industries and improve lives. Learn more at geventures.com.

Imagination at work

One focus: a shared commitment to improve the lives of cancer patients everywhere.

At TAKEDA ONCOLOGY, we endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients.

This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, we are finding innovative ways to improve the treatment of cancer.

We’ve built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though we’ve made great strides in our fight against cancer, we are determined to do more – to work harder and to reach higher. We continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that we are today.

We know that our mission is not a quick or simple one, but we are up for the task: we aspire to cure cancer.
The Personalized Medicine Coalition, representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system.

For more information or to become a member:
www.personalizedmedicinecoalition.org
202.589.0070
1710 Rhode Island Ave, NW
Suite 700 · Washington, DC 20036

Attacking cancer is now personal.
We've developed new technology and processes to better fight advanced cancers. Using a revolutionary method of gene sequencing, our experts now deliver more precise medicine than ever before. We're providing these treatments to patients across the nation, giving more people a better quality of life.

Intermountain Precision Genomics | Healing for life
435.251.5780 • genomics@imail.org
For more information or to order a test, visit precisionscancer.org

#1 Healthcare
Most Complete and Most Integrated

✓ Population Care Management
✓ Comprehensive Healthcare Analytics
✓ Clinical Data Warehousing
✓ Health Information, Insurance Exchanges
✓ End-to-End Payer Applications
✓ CRM, ERP and More

oracle.com/healthcare or call 1.800.ORACLE.1

Copyright © 2019, Oracle and/or its affiliates. All rights reserved. Oracle and Java are registered trademarks of Oracle and/or its affiliates.
Highlights Of Past Conferences
SAVE THE DATE

12th Annual Personalized Medicine Conference

November 16-17, 2016
Joseph B. Martin Conference Center at Harvard Medical School, Boston

Join the conversation at #PMConf
Follow us on Twitter at @PartnersPersMed